Interview with Ala Ciobanu, General Manager, Roche Ukraine
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Address: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, Hertfordshire, AL7 1TW, United Kingdom
Tel: +44 (0)1707 366000
Web: http://www.roche.co.uk/portal/uk
Headquartered in Basel, Switzerland, Roche employs around 2,000 people in the UK in pharmaceuticals, based at Welwyn Garden City in Hertfordshire, and diagnostics, based at Burgess Hill in East Sussex.
The UK pharmaceuticals headquarters at Welwyn Garden City in Hertfordshire is home to Roche’ global pharmaceutical product development team, its pharmaceuticals sales and marketing teams and corporate functions.
The purpose built facility that opened in 2005 at Shire Park in Welwyn Garden City, reflects and supports the continued success of Roche’s pharmaceutical business.
In 2006 Roche’ UK diagnostics sales and marketing team relocated to a new purpose-built facility in Burgess Hill, East Sussex.
As the UK’s leading in-vitro diagnostics company, Roche has a dynamic UK sales and marketing team who consistently deliver growth above the market rate.
As one of the major pharmaceutical and diagnostic companies in the UK, Roche develops and provides an innovative range of products and services that help healthcare professionals improve the health and well-being of the UK population.
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
See our Cookie Privacy Policy Here
